BioStock: Lipum's CEO summarizes the half-year – continued positive study data
Lipum's report for the first half of 2024 highlights the positive interim results from the phase I study with SOL-116. The company has started preparations for phase II trials in rheumatoid arthritis, including initiating the collaboration with NorthX Biologics for the manufacturing of SOL-116. BioStock reached out to Lipum's CEO Ola Sandborgh to learn more about these development, as well as the audit report of the Horizon 2020 project which may result in them being liable for repayment.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se